Solid Biosciences Inc. Common Stock (SLDB)

About SLDB

Solid Biosciences Inc. develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, which is in phase 1/2 for the treatment of Duchenne muscular dystrophy. It develops SGT-212 for the treatment of Friedreich's ataxia that is in phase 1b clinical trial; SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia that is in precl…

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Employees

121

Website

www.solidbio.com/

Fundamentals

1-day range

$9.72$10.1

Market cap

$789.57M

P/E (trailing)

—

P/E (forward)

-5.59

EPS (trailing)

$-1.91

Dividend yield

—

Beta

2.45

Avg. volume

1.62M

Forecasts

12 analyst ratings

Solid Biosciences Inc. Common Stock Competitors

Chosen by industry and closest market cap.

• SLDB

  Solid Biosciences Inc. Common Stock

  $9.78

  ▼ 3.46%
  Market cap $789.57MP/E —
  $3.79$11.45
• SANA

  Sana Biotechnology Inc. Common Stock

  $3.93

  ▼ 3.91%
  Market cap $884.97MP/E —
  $2.61$6.55
• AGMB

  AgomAb Therapeutics NV American Depositary Shares

  $13.17

  ▼ 4.84%
  Market cap $665.83MP/E —
  $8.75$17.82
• ALLO

  Allogene Therapeutics Inc. Common Stock

  $2.01

  ▼ 3.83%
  Market cap $635.08MP/E —
  $1.04$4.46
• DNA

  Ginkgo Bioworks Holdings Inc. Class A Common Stock

  $6.98

  ▼ 3.93%
  Market cap $555.49MP/E —
  $5.37$17.58
• FDMT

  4D Molecular Therapeutics Inc. Common Stock

  $14.65

  ▼ 1.74%
  Market cap $527.47MP/E —
  $5.97$16.93
• TECX

  Tectonic Therapeutic Inc. Common Stock

  $35.69

  ▼ 2.75%
  Market cap $526.83MP/E —
  $14.39$39.53

P/E shows — for peers not currently carrying a live signal of their own.

Latest news

• Cantor Fitzgerald Maintains Overweight on Solid Biosciences, Raises Price Target to $26
  benzinga · 8/27/2026

Institutional Ownership

March 31, 2026

Total shares held

97.19M

Total value held

$697.46M

Institutional holders

140